Multiple Myeloma

Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
Updates in cell and gene therapy approvals 1:27
Updates in cell and gene therapy approvals
Bruce Levine • 27 Jan 2022
Exciting advances in CAR-T and TCR research 2:49
Exciting advances in CAR-T and TCR research
David Gilham • 22 Feb 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Improving education in cell therapy 1:33
Improving education in cell therapy
Emanuele Ostuni • 12 Apr 2021
The European cell & gene therapy landscape 1:27
The European cell & gene therapy landscape
Paige Bischoff • 17 Mar 2021
A non-gene edited approach to allogeneic CAR-T development 2:21
A non-gene edited approach to allogeneic CAR-T development
Filippo Petti • 6 Apr 2021
Investigating allogeneic iNKT cell therapy 8:28
Investigating allogeneic iNKT cell therapy
Marc van Dijk • 23 Feb 2021
CT053, anti-GPC3 CAR-T and targeting solid tumors 4:15
CT053, anti-GPC3 CAR-T and targeting solid tumors
Hong Ma • 19 Feb 2021
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community 2:49
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community
Ananda Plate • 11 Feb 2021
Novel strategies to optimize CAR T-cell therapy 4:31
Novel strategies to optimize CAR T-cell therapy
Arnon Nagler • 1 Feb 2021
CAR T-cells in myeloma: patients’ perspective 1:52
CAR T-cells in myeloma: patients’ perspective
Ananda Plate • 11 Feb 2021
The importance of partnering with patient organizations 3:48
The importance of partnering with patient organizations
Ananda Plate • 11 Feb 2021
Progression of CAR-T trials in China 2:19
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
CAR-T trials to watch in China 3:21
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021
CAR-T in myeloma: key players in the therapeutic landscape 4:32
CAR-T in myeloma: key players in the therapeutic landscape
Mohamad Mohty • 26 Jan 2021
The content of VJRegenMed is intended for healthcare professionals